Back to search
Hemolytic-uremic Syndrome
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hemolytic-uremic Syndrome trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hemolytic-uremic Syndrome trials you may qualify forThis is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aH…
Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samp…
The purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study parti…
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic sy…
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed…
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases…
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatme…
The investigators aim to perform the first controlled randomized prospective study using ECZ in pediatric STEC-HUS. This is of great interest as there is still…
This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric…